

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Multiple myeloma (MM)	Bromodomain containing 4 (BRD4)	<p>Studies in mice and patient samples suggest inhibiting BRD4 could help treat MM. In a panel of patient-derived MM cells, the small molecule bromodomain inhibitor JQ1 decreased proliferation compared with vehicle control. In mouse models of MM, JQ1 lowered tumor burden and prolonged survival compared with vehicle control. Next steps include testing additional bromodomain inhibitors in preclinical models.</p> <p>Tensha Therapeutics Inc., a new company founded by James Bradner, has bromodomain inhibitors in preclinical development for cancer indications.</p> <p><b>SciBX 4(36); doi:10.1038/scibx.2011.1015</b> Published online Sept. 15, 2011</p>	Patent application filed; exclusively licensed to Tensha Therapeutics	<p>Delmore, J.E. <i>et al. Cell</i>; published online Sept. 1, 2011; doi:10.1016/j.cell.2011.08.017</p> <p><b>Contact:</b> Constantine S. Mitsiades, Dana-Farber Cancer Institute, Boston, Mass. e-mail: <a href="mailto:constantine_mitsiades@dfci.harvard.edu">constantine_mitsiades@dfci.harvard.edu</a></p> <p><b>Contact:</b> James E. Bradner, same affiliation as above e-mail: <a href="mailto:james_bradner@dfci.harvard.edu">james_bradner@dfci.harvard.edu</a></p>